Apexigen rises after positive cancer therapy data
12/09/2022 12:06
** Drug developer Apexigen Inc's shares APGN.O rise 5.8%
to $8.05 premarket
** Says experimental combination therapy to treat patients
with cancer of digestive system, when compared with standard of
care treatment, showed efficacy in mid-stage study urn:newsml:reuters.com:*:nGNX41BJgp
** Combination therapy in trial was generally well-tolerated
amongst the participant and safe to use - APGN
** Esophageal or gastroesophageal junction cancer is rare
cancer, which grows in food pipe connecting mouth with stomach
affecting 1 out of 100,000 people, according to NIH
** Up to Friday's close, stock down ~19%, since Co's IPO in
Feb 2022
(Reporting by Khushi Mandowara)
((Khushi.Mandowara@thomsonreuters.com;))
Recent news on Apexigen
See all newsBrief: Apexigen Inc - On August 15, Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard Transfer Of Listing From Nasdaq
Brief: Apexigen Says Phase 2 Data Evaluating Sotigalimab, Its CD40 Agonist Antibody, In Combination With Doxorubicin Marked Increases In Overall Survival Observed Across Soft Tissue Sarcoma Patients
Apexigen rises on buyout deal with Pyxis Oncology
Brief: Pyxis Oncology To Acquire Apexigen For Total Enterprise Value Of About $16 Million
Brief: Apexigen Inc Says On April 11, Co Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq